<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width,initial-scale=1" />
  <title>Cape Porpoise Clinical Consulting</title>
  <meta name="description" content="Clinical and regulatory consulting for early-stage biotech. Strategy to execution." />
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Libre+Baskerville:ital,wght@0,400;0,700;1,400&family=DM+Sans:opsz,wght@9..40,400;9..40,500;9..40,600&display=swap" rel="stylesheet">

  <style>
    :root {
      --ink: #0e1219;
      --paper: #f7f4ef;
      --muted: #6b6660;
      --accent: #1a3a5c;
      --rule: #d4cfc7;
      --serif: 'Libre Baskerville', Georgia, serif;
      --sans: 'DM Sans', system-ui, sans-serif;
    }

    *, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }
    html { scroll-behavior: smooth; }

    body {
      font-family: var(--sans);
      background: var(--paper);
      color: var(--ink);
      line-height: 1.6;
    }

    nav {
      position: sticky;
      top: 0;
      z-index: 100;
      background: rgba(247,244,239,.95);
      backdrop-filter: blur(10px);
      border-bottom: 1px solid var(--rule);
      padding: 0 48px;
      display: flex;
      justify-content: space-between;
      align-items: center;
      height: 64px;
    }

    .brand {
      display: flex;
      align-items: center;
      gap: 13px;
      text-decoration: none;
      color: var(--ink);
    }

    .brand-text { line-height: 1; }

    .brand-name {
      display: block;
      font-family: var(--serif);
      font-size: 13px;
      letter-spacing: .12em;
      text-transform: uppercase;
    }

    .brand-sub {
      display: block;
      font-size: 10px;
      letter-spacing: .07em;
      text-transform: uppercase;
      color: var(--muted);
      margin-top: 3px;
    }

    .nav-links { display: flex; gap: 24px; list-style: none; }

    .nav-links a {
      font-size: 12px;
      font-weight: 600;
      letter-spacing: .07em;
      text-transform: uppercase;
      color: var(--muted);
      text-decoration: none;
      transition: color .15s;
    }

    .nav-links a:hover { color: var(--ink); }

    .hero {
      min-height: 84vh;
      display: flex;
      flex-direction: column;
      justify-content: flex-end;
      padding: 72px 48px;
      border-bottom: 1px solid var(--rule);
    }

    .eyebrow {
      font-size: 11px;
      font-weight: 600;
      letter-spacing: .18em;
      text-transform: uppercase;
      color: var(--muted);
      margin-bottom: 22px;
      display: flex;
      align-items: center;
      gap: 12px;
      opacity: 0;
      animation: up .6s ease .1s forwards;
    }

    .eyebrow::before {
      content: '';
      width: 24px;
      height: 1px;
      background: var(--muted);
      flex-shrink: 0;
    }

    h1 {
      font-family: var(--serif);
      font-size: clamp(34px, 5.5vw, 72px);
      line-height: 1.08;
      letter-spacing: -.02em;
      max-width: 820px;
      margin-bottom: 32px;
      opacity: 0;
      animation: up .7s ease .2s forwards;
    }

    h1 em { font-style: italic; color: var(--accent); }

    .cta-row {
      display: flex;
      gap: 14px;
      align-items: center;
      opacity: 0;
      animation: up .7s ease .33s forwards;
    }

    .btn {
      background: var(--accent);
      color: #fff;
      padding: 13px 24px;
      border-radius: 3px;
      text-decoration: none;
      font-size: 13px;
      font-weight: 600;
      letter-spacing: .04em;
      transition: opacity .15s;
    }

    .btn:hover { opacity: .85; }

    section { border-bottom: 1px solid var(--rule); }

    .row {
      max-width: 1060px;
      margin: 0 auto;
      padding: 72px 48px;
      display: grid;
      grid-template-columns: 180px 1fr;
      gap: 52px;
    }

    .label {
      font-size: 10.5px;
      font-weight: 700;
      letter-spacing: .18em;
      text-transform: uppercase;
      color: var(--muted);
      padding-top: 4px;
    }

    .body-lg {
      font-size: 18px;
      line-height: 1.7;
      max-width: 660px;
      margin-bottom: 20px;
    }

    .body-lg:last-child { margin-bottom: 0; }

    /* TAG GROUPS */
    .tag-group { margin-bottom: 28px; }
    .tag-group:last-child { margin-bottom: 0; }

    .tag-group-title {
      font-size: 10.5px;
      font-weight: 700;
      letter-spacing: .16em;
      text-transform: uppercase;
      color: var(--muted);
      margin-bottom: 10px;
    }

    .tags { display: flex; flex-wrap: wrap; gap: 7px; }

    .tag {
      font-size: 13px;
      color: var(--ink);
      border: 1px solid var(--rule);
      padding: 5px 13px;
      border-radius: 999px;
      background: #fff;
    }

    /* STAT GRIDS */
    .stat-grid {
      display: grid;
      gap: 1px;
      background: var(--rule);
      border: 1px solid var(--rule);
      border-radius: 5px;
      overflow: hidden;
    }

    .stat-grid-4 { grid-template-columns: repeat(4, 1fr); }
    .stat-grid-3 { grid-template-columns: repeat(3, 1fr); }

    .stat-cell {
      background: var(--paper);
      padding: 24px 20px;
    }

    .stat-cell strong {
      display: block;
      font-family: var(--serif);
      font-size: 36px;
      color: var(--accent);
      line-height: 1;
      margin-bottom: 8px;
    }

    .stat-cell span {
      font-size: 12.5px;
      color: var(--muted);
      line-height: 1.45;
    }

    /* CHART */
    .chart-label {
      font-size: 10.5px;
      font-weight: 700;
      letter-spacing: .16em;
      text-transform: uppercase;
      color: var(--muted);
      margin-bottom: 14px;
      margin-top: 36px;
    }

    .chart-outer {
      border: 1px solid var(--rule);
      border-radius: 5px;
      padding: 24px 24px 0;
      background: var(--paper);
    }

    .bars {
      display: flex;
      align-items: flex-end;
      gap: 10px;
      height: 110px;
      border-bottom: 1px solid var(--rule);
    }

    .bar-col { flex: 1; }

    .bar-fill {
      width: 100%;
      background: var(--accent);
      border-radius: 2px 2px 0 0;
    }

    .bar-labels {
      display: flex;
      gap: 10px;
      padding: 10px 0 16px;
    }

    .bar-lbl {
      flex: 1;
      text-align: center;
      font-size: 11px;
      color: var(--muted);
      line-height: 1.5;
    }

    .bar-lbl strong {
      display: block;
      font-size: 12px;
      color: var(--ink);
      font-weight: 600;
    }

    .chart-source {
      font-size: 11.5px;
      color: var(--muted);
      line-height: 1.55;
      padding: 12px 0 20px;
      border-top: 1px solid var(--rule);
      margin-top: 4px;
    }

    /* SERVICES */
    .svc-cols {
      display: grid;
      grid-template-columns: 1fr 1fr;
      gap: 1px;
      background: var(--rule);
      border: 1px solid var(--rule);
      border-radius: 5px;
      overflow: hidden;
      width: 100%;
    }

    .svc-col { background: var(--paper); padding: 32px 28px; }

    .svc-col-label {
      font-size: 10px;
      font-weight: 700;
      letter-spacing: .17em;
      text-transform: uppercase;
      color: var(--muted);
      margin-bottom: 5px;
    }

    .svc-col-title {
      font-family: var(--serif);
      font-size: 19px;
      line-height: 1.2;
      margin-bottom: 7px;
    }

    .svc-desc {
      font-size: 13.5px;
      color: var(--muted);
      line-height: 1.55;
      margin-bottom: 20px;
      padding-bottom: 20px;
      border-bottom: 1px solid var(--rule);
    }

    .svc-list { list-style: none; display: flex; flex-direction: column; gap: 10px; }

    .svc-list li {
      font-size: 14px;
      color: var(--muted);
      line-height: 1.45;
      padding-left: 14px;
      position: relative;
    }

    .svc-list li::before {
      content: '';
      position: absolute;
      left: 0;
      top: 9px;
      width: 5px;
      height: 1px;
      background: var(--rule);
    }

    /* ABOUT */
    .about-body p {
      font-size: 15.5px;
      line-height: 1.78;
      color: var(--muted);
      margin-bottom: 16px;
      max-width: 660px;
    }

    .about-body p:last-child { margin-bottom: 0; }
    .about-body strong { color: var(--ink); font-weight: 600; }

    .about-body a {
      color: var(--accent);
      text-decoration: none;
      border-bottom: 1px solid var(--rule);
      transition: border-color .15s;
    }

    .about-body a:hover { border-color: var(--accent); }

    /* CONTACT */
    .contact-tag {
      font-family: var(--serif);
      font-size: 25px;
      line-height: 1.3;
      margin-bottom: 28px;
      max-width: 440px;
    }

    .contact-links { display: flex; flex-direction: column; margin-bottom: 24px; }

    .contact-link {
      display: flex;
      justify-content: space-between;
      align-items: center;
      font-size: 16px;
      font-weight: 500;
      color: var(--accent);
      text-decoration: none;
      padding: 13px 0;
      border-bottom: 1px solid var(--rule);
      transition: color .15s;
    }

    .contact-link:first-child { border-top: 1px solid var(--rule); }
    .contact-link:hover { color: #2d5f8a; }

    .arr { transition: transform .15s; }
    .contact-link:hover .arr { transform: translateX(4px); }

    .contact-note { font-size: 13px; color: var(--muted); line-height: 1.65; max-width: 380px; }

    footer {
      padding: 22px 48px;
      display: flex;
      justify-content: space-between;
      flex-wrap: wrap;
      gap: 8px;
    }

    footer p { font-size: 12px; color: var(--muted); }

    @keyframes up {
      from { opacity: 0; transform: translateY(20px); }
      to   { opacity: 1; transform: translateY(0); }
    }

    @media (max-width: 780px) {
      nav { padding: 0 20px; }
      .nav-links { display: none; }
      .brand-sub { display: none; }
      .hero { padding: 56px 20px; min-height: 68vh; }
      .row { grid-template-columns: 1fr; gap: 14px; padding: 52px 20px; }
      .svc-cols { grid-template-columns: 1fr; }
      .stat-grid-4 { grid-template-columns: 1fr 1fr; }
      .stat-grid-3 { grid-template-columns: 1fr 1fr; }
      footer { padding: 18px 20px; }
    }
  </style>
</head>

<body>

  <nav>
    <a class="brand" href="#top">
      <div class="brand-text">
        <span class="brand-name">CPCC</span>
        <span class="brand-sub">Cape Porpoise Clinical Consulting</span>
      </div>
    </a>
    <ul class="nav-links">
      <li><a href="#focus">Focus</a></li>
      <li><a href="#industrytrends">Industry Trends</a></li>
      <li><a href="#expertise">Expertise</a></li>
      <li><a href="#credentials">Track Record</a></li>
      <li><a href="#about">About</a></li>
      <li><a href="#contact">Contact</a></li>
    </ul>
  </nav>

  <div class="hero" id="top">
    <div class="eyebrow">Cape Porpoise Clinical Consulting &middot; Cambridge, MA</div>
    <h1>Helping lean biotech<br>chart a course to <em>meaningful clinical inflection points.</em></h1>
    <div class="cta-row">
      <a class="btn" href="#contact">Get in touch</a>
    </div>
  </div>

  <!-- FOCUS + SERVICES COMBINED -->
  <section id="focus">
    <div class="row">
      <div class="label">What we do</div>
      <div>
        <p class="body-lg">CPCC works exclusively with <strong>early clinical-stage biotech companies</strong> to efficiently navigate the path from candidate selection and confirmation to meaningful clinical inflection points: the data, regulatory decisions, and milestones that unlock program advancement and company growth.</p>
        <p class="body-lg">Whether you need a senior thought partner to support interactions with inbounds, the board, or regulatory authorities, or just need someone to build the clinical and regulatory infrastructure and get the work done, CPCC covers the full range. High-level development strategy through hands-on execution and submission-ready deliverables.</p>
        <p class="body-lg" style="margin-bottom:36px;">CPCC embeds directly with your team — large or small. For lean startups without a full clinical function, Amanda can serve as a fractional head of clinical development and regulatory affairs, owning strategy and execution end to end. For larger teams, she plugs in to lead specific workstreams, fill senior gaps, or provide surge capacity at critical moments.</p>

        <div class="svc-cols">
          <div class="svc-col">
            <div class="svc-col-label">Strategic</div>
            <div class="svc-col-title">Advisory and Consulting</div>
            <p class="svc-desc">Senior judgment at the table for investor and regulatory interactions and program-level planning.</p>
            <ul class="svc-list">
              <li>Clinical and regulatory development strategy</li>
              <li>Trial design and endpoint selection</li>
              <li>FDA meeting preparation and participation</li>
              <li>Investor and board-level scientific and operational advisory</li>
              <li>Clinical and regulatory risk assessment</li>
              <li>Partnership and due diligence support</li>
            </ul>
          </div>
          <div class="svc-col">
            <div class="svc-col-label">Execution</div>
            <div class="svc-col-title">Clinical and Regulatory Work</div>
            <p class="svc-desc">Submission-ready deliverables built directly. First drafts that hold up through review.</p>
            <ul class="svc-list">
              <li>Medical writing: IBs, protocols, ICFs, CSRs</li>
              <li>IND and CTA preparation and submission</li>
              <li>Regulatory correspondence and agency responses</li>
              <li>Clinical trial project management</li>
              <li>Data management and pharmacovigilance oversight</li>
              <li>Vendor oversight and operational problem-solving</li>
              <li>QC and narrative coherence review</li>
            </ul>
          </div>
        </div>
      </div>
    </div>
  </section>

  <!-- INDUSTRY TRENDS -->
  <section id="industrytrends">
    <div class="row">
      <div class="label">Clinical Data Fuels M&amp;A</div>
      <div>
        <p class="body-lg">The market has fundamentally reoriented around clinical data. Pharma is spending more than ever on licensing and acquisitions, but concentrating it across <strong>fewer, higher-conviction deals</strong> — rewarding companies that reach meaningful clinical readouts with well-designed trials and credible data packages. Preclinical-stage companies are increasingly shut out. The inflection point is everything.</p>

        <div class="stat-grid stat-grid-3" style="margin-top:36px;margin-bottom:36px;">
          <div class="stat-cell">
            <strong>$108B</strong>
            <span>Pharma licensing spend in 2024 — highest in a decade — but across far fewer deals than historically</span>
          </div>
          <div class="stat-cell">
            <strong>4x</strong>
            <span>Drop in preclinical-stage IPO value in 2024 vs 2023 — public investors shifting hard toward clinical-stage assets</span>
          </div>
          <div class="stat-cell">
            <strong>109%</strong>
            <span>Increase in VC financing for Phase II/III deals in Q1 2024 vs Q4 2023 — capital following clinical proof</span>
          </div>
        </div>

        <div class="chart-label">Biopharma M&amp;A deal value (USD billions) &mdash; LSEG / IQVIA</div>
        <div class="chart-outer">
          <div class="bars">
            <div class="bar-col"><div class="bar-fill" style="height:38px;opacity:.55;"></div></div>
            <div class="bar-col"><div class="bar-fill" style="height:85px;opacity:.7;"></div></div>
            <div class="bar-col"><div class="bar-fill" style="height:32px;opacity:.5;"></div></div>
            <div class="bar-col"><div class="bar-fill" style="height:110px;opacity:1;"></div></div>
            <div class="bar-col"><div class="bar-fill" style="height:86px;opacity:.85;"></div></div>
          </div>
          <div class="bar-labels">
            <div class="bar-lbl">2020<strong>$98B</strong></div>
            <div class="bar-lbl">2021<strong>$189B</strong></div>
            <div class="bar-lbl">2022<strong>$84B</strong></div>
            <div class="bar-lbl">2023<strong>$244B</strong></div>
            <div class="bar-lbl">2024<strong>$191B</strong></div>
          </div>
          <p class="chart-source">Sources: LSEG, IQVIA, McKinsey, GlobalData. M&amp;A values reflect majority-stake biopharma acquisitions exceeding $1B. From 2022 onward, dealmaking shifted decisively toward clinical-stage assets. Pharma licensing spend hit $108B in 2024 — the highest in a decade — but distributed across only 257 deals vs. a pre-2020 average of 429.</p>
        </div>
      </div>
    </div>
  </section>

  <!-- EXPERTISE -->
  <section id="expertise">
    <div class="row">
      <div class="label">Expertise</div>
      <div>
        <div class="tag-group">
          <div class="tag-group-title">Therapeutic Areas</div>
          <div class="tags">
            <span class="tag">Cardiovascular</span>
            <span class="tag">Neurology</span>
            <span class="tag">Rare Disease</span>
            <span class="tag">Oncology</span>
            <span class="tag">Respiratory</span>
            <span class="tag">Microbiome / GI</span>
          </div>
        </div>
        <div class="tag-group">
          <div class="tag-group-title">Modalities</div>
          <div class="tags">
            <span class="tag">Antibody-Protein Fusions</span>
            <span class="tag">Antibody-Drug Conjugates</span>
            <span class="tag">Bispecific Antibodies</span>
            <span class="tag">RNAi / siRNA</span>
            <span class="tag">Small Molecules</span>
            <span class="tag">Combination Drug / Device Products</span>
            <span class="tag">Inhaled Drug Delivery</span>
            <span class="tag">Microbiome Therapeutics</span>
          </div>
        </div>
        <div class="tag-group">
          <div class="tag-group-title">Functional Areas</div>
          <div class="tags">
            <span class="tag">Regulatory Affairs</span>
            <span class="tag">Medical Writing</span>
            <span class="tag">Clinical Operations</span>
            <span class="tag">Data Management</span>
            <span class="tag">Pharmacovigilance</span>
            <span class="tag">Program Management</span>
            <span class="tag">Vendor Selection &amp; Oversight</span>
          </div>
        </div>
        <div class="tag-group">
          <div class="tag-group-title">Companies</div>
          <div class="tags">
            <span class="tag">Salubris Biotherapeutics</span>
            <span class="tag">Acorda Therapeutics</span>
            <span class="tag">Dicerna Pharmaceuticals</span>
            <span class="tag">Nocion Therapeutics</span>
            <span class="tag">Elevian</span>
            <span class="tag">Finch Therapeutics</span>
            <span class="tag">Pharmica Consulting</span>
          </div>
        </div>
      </div>
    </div>
  </section>

  <!-- TRACK RECORD -->
  <section id="credentials">
    <div class="row">
      <div class="label">Track Record</div>
      <div>
        <p class="body-lg" style="margin-bottom:36px;">Over 18 years inside small and midsize biotech across Boston and Cambridge, Amanda has guided programs from first-in-human through FDA approval, exits, and partnerships. Two FDA-approved drugs. Twelve INDs. Three NDA contributions. A career built entirely in small biotech — wearing many hats, working across every function, and knowing how to move programs forward with lean teams and limited resources.</p>
        <div class="stat-grid stat-grid-4">
          <div class="stat-cell"><strong>18+</strong><span>Years in clinical biotech leadership</span></div>
          <div class="stat-cell"><strong>12+</strong><span>INDs filed</span></div>
          <div class="stat-cell"><strong>3</strong><span>NDA contributions</span></div>
          <div class="stat-cell"><strong>2</strong><span>FDA-approved therapies</span></div>
        </div>
      </div>
    </div>
  </section>

  <!-- ABOUT -->
  <section id="about">
    <div class="row">
      <div class="label">About</div>
      <div class="about-body">
        <p>CPCC is led by <strong>Amanda McEwen</strong> — <a href="https://www.linkedin.com/in/amandamariegentilemcewen/" target="_blank" rel="noopener">LinkedIn</a> — SVP of Clinical Development at Salubris Biotherapeutics, where she leads the JK07 program, a first-in-class ErbB4 agonist in Phase 2b for heart failure.</p>
        <p>Amanda is a career small-biotech professional. Over 18 years she has worked inside lean teams where clinical, regulatory, operations, data management, and pharmacovigilance often fall to the same handful of people. That experience — wearing many hats, building programs from scratch, and knowing how to move fast without cutting corners — is exactly what CPCC brings to client teams. She embeds fluidly with both small founding teams that need a full clinical function built out, and larger organizations that need senior capacity on a specific workstream or at a critical juncture.</p>
        <p>Her programs include contributions to two FDA-approved therapies: <strong>Inbrija</strong> (inhaled levodopa for Parkinson's OFF episodes, approved 2018) and <strong>Rivfloza</strong> (for primary hyperoxaluria type 1). Her work spans antibody fusions, ADCs, RNAi, inhaled delivery, small molecules, and microbiome therapeutics across neurology, cardiovascular, rare disease, oncology, pain, and GI.</p>
        <p>She is an <strong>Executive Fellow at Harvard Business School</strong> in entrepreneurship and life sciences, and <strong>adjunct faculty at Northeastern University</strong> in the MS in Regulatory Affairs program.</p>
      </div>
    </div>
  </section>

  <!-- CONTACT -->
  <section id="contact">
    <div class="row">
      <div class="label">Contact</div>
      <div>
        <p class="contact-tag">Let's talk about where your program is and what it needs to get to the next inflection point.</p>
        <div class="contact-links">
          <a class="contact-link" href="mailto:amanda.gentile@gmail.com">amanda.gentile@gmail.com <span class="arr">&#8594;</span></a>
          <a class="contact-link" href="tel:+16176459160">617 645 9160 <span class="arr">&#8594;</span></a>
        </div>
        <p class="contact-note">First call covers program stage, near-term goals, key deliverables, and timeline. A simple statement of work follows. No long procurement cycles.</p>
      </div>
    </div>
  </section>

  <footer>
    <p>&#169; <span id="y"></span> Cape Porpoise Clinical Consulting</p>
    <p>Cambridge, Massachusetts</p>
  </footer>

  <script>document.getElementById("y").textContent = new Date().getFullYear();</script>
</body>
</html>
